Abstract: The present invention is a method of evaluating a shape of a semiconductor wafer comprising the steps of: measuring shape data of a semiconductor wafer by scanning a front surface and/or a back surface of the semiconductor wafer; calculating a differential profile through a differential process of the measured shape data; analyzing the obtained differential profile and obtaining a surface characteristic of the wafer, and; evaluating a shape of the semiconductor wafer. Thereby, there are provided a method of evaluating a shape of a semiconductor wafer and an apparatus for evaluating a shape thereof, wherein a shape of a semiconductor wafer, particularly a shape of a peripheral portion of the wafer, can be quantitatively evaluated from a viewpoint different from conventional SFQR etc., and the shape quality of the wafer can be accurately evaluated over a specification of a strict design rule.

Abstract: The present invention provides a method for preparing an aryl 5-thio-?-D-aldohexopyranoside derivative of Formula (III), which comprises reacting a 5-thio-D-aldohexopyranose derivative of Formula (I) with Ar—OH of Formula (II) in the presence of a phosphine represented by PR11R12R13 and an azo reagent represented by R21—N?N—R22 in accordance with the following scheme.

Abstract: The following compounds useful as VEGF receptor antagonists and having excellent physical properties are provided. A carboxylic acid derivative represented by formula: wherein ring A represents a benzene ring, a naphthalene ring, or the like; W represents a C1-5 alkylene group; Z represents a single bond or a phenylene group; R1 and R2 are the same or different and each represents a hydrogen atom, a halogen atom, a C1-5 alkyl group or a C1-10 alkoxy group; R3 represents a hydrogen atom, a halogen atom, a C1-12 alkyl group, a C2-5 alkynyl group, a trifluoromethyl group, an acetylenyl group, a cyano group, a nitro group, —CH2—R6, —Y—R11, or the like; R4 represents a group represented by formula: and R5 represents a hydrogen atom or a C1-5 alkyl group, or a pharmaceutical acceptable salt of the derivative.

Abstract: There is provided a 5-thio-?-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

Abstract: A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.

Abstract: An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.

Abstract: An electromagnetic absorber formed of conductive fiber or the like, such as carbon fiber having an overall length corresponding to the wavelength of electromagnetic waves to be absorbed, is mixed into a base material to form an electromagnetic wave-absorbing pavement material. The electromagnetic wave-absorbing pavement material is used to form a pavement having an electromagnetic wave absorbing course. Further, an electromagnetic wave reflecting course is disposed under the electromagnetic wave absorbing course, and the electric length of the electromagnetic wave reflecting course is set to a predetermined value in relation to the dielectric constant so that electromagnetic waves reflecting off the surface of the electromagnetic wave absorbing course and electromagnetic waves reflecting off the electromagnetic wave reflecting course have opposite phases and thereby cancel each other out, whereby the electromagnetic waves are absorbed well.

Abstract: An object of the present invention is to provide a job management method for making it possible to reuse jobs in an ETL process. In the job management method, a job information table is accessed, jobs having table attributes and data field attributes matching between the respective jobs are retrieved, and, for each retrieved job, matching degrees of the data field attribute of “other jobs” in which the matching has been confirmed are calculated. Then, the “other jobs” in which the calculated matching degrees is equal to or more than a predetermined level are identified, and the identified “other jobs” are outputted to an output interface.

Abstract: The present invention relates to a semiconductor wafer, wherein the semiconductor wafer has a shape in which the outer peripheral portion of the semiconductor wafer bends in such a manner as to swell (rises) on the wafer front surface and bends in such a manner as to droop (sags) on the wafer back surface. Thus, there is provided a semiconductor wafer capable of forming device patterns on the wafer with high yield despite shape variation in a wafer chuck of an exposure apparatus in the photolithography step and polishing the wafer with uniform stock removal in CMP in a device production process.

Abstract: A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors according to the present invention are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.

Abstract: Aminobenzoic acid derivatives represented by Formula (1) as follows: (wherein, R1 represents a hydrogen atom, a C1-6alkyl group, or the like; R2 represents a hydrogen atom, a C1-6alkyl group, or the like; R3 represents a C8-25alkyl group, or the like; R4 represents a hydrogen atom or a group represented by OR9 or CO2R10 (wherein R9 and R10 represent a hydrogen atom or a C1-6 alkyl group); A represents a group represented by S(O)qR15 (wherein q is 0, 1, or 2, R15 represents a C1-6alkyl group, a phenyl C1-3alkyl group, or a group represented by (CH2)mOR16 (wherein m is 2 or 3, and R16 represents a hydrogen atom or a methoxymethyl group), or the like; X represents O, a single bond, CH═CH, or a group represented by NR27 (wherein R27 represents a hydrogen atom or a t-butoxycarbonyl group); Y represents O, CONH, NHCO, or a group represented by NR28 (wherein R28 represents a hydrogen atom or a t-butoxycarbonyl group); and n is an integer of 0 to 15) or pharmaceutically acceptable salts of the

Abstract: Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided.

Abstract: A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability in a medium having pH of 5.0 or less, wherein a total content of an organic acid that inhibits growth of the microorganism at the pH is one at which the growth of the microorganism is not inhibited; and a method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability at a first pH at which growth of the microorganism is not inhibited by an organic acid in a medium, and then culturing the microorganism at a second pH that is suitable for L-glutamic acid production by the microorganism and is lower than the first pH.

Abstract: A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability in a liquid medium of which pH is adjusted to a condition under which L-glutamic acid produced by the microorganism is allowed to be precipitated, to allow L-glutamic acid to be produced and accumulated with precipitation of L-glutamic acid accompanied, wherein an operation causing existence of L-glutamic acid crystals in the medium is performed when a concentration of L-glutamic acid in the medium is lower than the concentration at which spontaneous crystallization occurs.

Abstract: Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided.

Abstract: A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability at a first pH that is suitable for growth of the microorganism, and then culturing the microorganism at a second pH that is suitable for L-glutamic acid production by the microorganism and is lower than the first pH.

Abstract: A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability in a medium having pH of 5.0 or less, wherein a total content of an organic acid that inhibits growth of the microorganism at the pH is one at which the growth of the microorganism is not inhibited; and a method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability at a first pH at which growth of the microorganism is not inhibited by an organic acid in a medium, and then culturing the microorganism at a second pH that is suitable for L-glutamic acid production by the microorganism and is lower than the first pH.

Abstract: A method for producing L-glutamic acid by fermentation, which comprises culturing a microorganism having L-glutamic acid-producing ability at a first pH that is suitable for growth of the microorganism, and then culturing the microorganism at a second pH that is suitable for L-glutamic acid production by the microorganism and is lower than the first pH.

Abstract: The high quality silicon wafer of large diameter is invented by mainly paying attention to the particles ascribed to the crystal and the wafer is optimal for manufacturing ultra highly integrated devices. The silicon wafer is of diameter of 300 mm and larger sliced from a single-crystal silicon ingot pulled by CZ method, the surface is mirror-polished and cleaned with ammonia based cleaning solution, and the number of particles of 0.083 &mgr;m and larger in size detected on its main surface is 120 and smaller and/or particles of 0.090 &mgr;m and larger in size is smaller than 80.